Enabling Global Health Solutions

With the increasing popularity of the GeneXpert® System, as well as the technology’s enormous potential to facilitate the diagnosis of multiple diseases in individual patients, Cepheid recognizes its responsibility in continuing critical test development and enabling platform access beyond the traditional laboratory.

A Global Need For Better Choices

Globally, these are mission-critical for Cepheid as a leading diagnostics company — because control of worldwide health threats may be hampered when testing is performed only in centralized labs, far from where patients live. Patients often travel long distances for diagnostic testing, or their samples must be transported — which may delay test results and impact patient care. Moreover, test results may get lost or never make it back to the patients.

A Mission to Deliver Progress to Everyone

Decentralization of testing facilities increases access and improves patient outcomes, as shown by recent studies from countries like Malawi1, where infants were tested for HIV both immediately at the point of care and by sending samples to a remote laboratory. More results were delivered to clinicians and more babies treated when tested locally.

The more than 10,000 GeneXpert Systems that have been installed in low and middle-income countries2, mainly for the diagnosis of active tuberculosis, can also be used to run tests for the nearly 30 CE-IVD3 Xpert tests now available.

Click here to download the Framework for GeneXpert Systems HIV and TB Integration

Outcomes That Speak For Themselves

Global health organizations, countries, donors and other stakeholders have been encouraging and supporting the more integrated, efficient use of diagnostics to work toward WHO targets for eliminating diseases such as HIV4, tuberculosis, HCV4 and cervical cancer.

"Unitaid has made significant investments in advancing integration in molecular diagnostics. Integrating care means more people healed, more lives saved, more efficient use of resources," Unitaid Executive Director Lelio Marmora said. "Now we need manufacturers to share in the responsibility of making sure these technologies work seamlessly in countries as part of sustainable systems."

"Integrating care means more people healed, more lives saved, more efficient use of resources. Now we need manufacturers to share in the responsibility of making sure these technologies work seamlessly in countries as part of sustainable systems."

Xpert® MTB/RIF Ultra

Xpert® MTB/RIF Ultra

Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis in less than 80 minutes
Xpert® HIV-1 Viral Load

Xpert® HIV-1 Viral Load

Dual Target Detection for Extended Coverage and Superior Performance
Xpert® HIV-1 Qual

Xpert® HIV-1 Qual

Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in around 90 minutes
Xpert® HPV

Xpert® HPV

Reliable Detection of High-Risk HPV DNA with Genotyping of HPV 16 and 18/45
Xpert® HCV Viral Load

Xpert® HCV Viral Load

Highly sensitive, timely results for effective patient management and improved access to testing.
Xpert® HBV Viral Load

Xpert® HBV Viral Load

Detection and quantitation of Hepatitis B virus (HBV) in less than one hour

1. Mwenda et al. Significantly improved antiretroviral therapy initiation rates after implementation of Point of Care Early Infant Diagnosis. ASLM 2016

2. HBDC Access Program covers 130 Low and Middle-income countries. Conditions can be found on the FIND website (https://www.finddx.org/pricing/genexpert/)

3. Some products not available in the US